Protagenic Therapeutics, Inc.\new Proceeds from Notes Payable
Protagenic Therapeutics, Inc.\new (PTIX) reported Proceeds from Notes Payable of $1.62 million for the 12-month period ending 2025-03-31, per its 10-K filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-14
- Protagenic Therapeutics, Inc.\new proceeds from notes payable for the quarter ending 2025-03-31 was -$374.96K.
- Protagenic Therapeutics, Inc.\new proceeds from notes payable for the quarter ending 2024-12-31 was $150.23K.
- Protagenic Therapeutics, Inc.\new proceeds from notes payable for the quarter ending 2024-09-30 was $670.13K.
- Protagenic Therapeutics, Inc.\new proceeds from notes payable for the quarter ending 2024-06-30 was $1.18M.
- Protagenic Therapeutics, Inc.\new proceeds from notes payable for fiscal 2025 was $1.62M.
- Protagenic Therapeutics, Inc.\new proceeds from notes payable for fiscal 2020 was $1.18M.
- Protagenic Therapeutics, Inc.\new proceeds from notes payable for fiscal 2015 was $340.00K, a 94.29% increase from fiscal 2014.
- Protagenic Therapeutics, Inc.\new proceeds from notes payable for fiscal 2014 was $175.00K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2025-03-31 | -$374.96K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | -$224.73K derived: sum of 2 quarters · filed 2026-08-14 | $445.40K derived: sum of 3 quarters · filed 2026-08-14 | $1.62M 10-K · filed 2026-08-14 |
| 2024-12-31 | $150.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | $820.36K derived: sum of 2 quarters · filed 2026-03-09 | $2.00M 10-Q · filed 2026-03-09 | |
| 2024-09-30 | $670.13K derived: 10-Q 6 month − 10-QT 3 month · filed 2025-11-26 | $1.85M 10-Q · filed 2025-11-26 | ||
| 2024-06-30 | $1.18M 10-QT · filed 2025-09-10 | |||
| 2021-09-30 | $100.00K 10-Q · filed 2022-11-14 | |||
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-13 | $100.00K derived: sum of 2 quarters · filed 2022-05-13 | $427.50K derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-07 | $327.50K derived: sum of 2 quarters · filed 2022-04-07 | $1.18M 10-K · filed 2022-04-07 | |
| 2020-09-30 | $327.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.18M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $850.00K 10-Q · filed 2021-08-16 | |||
| 2015-12-31 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-03-11 | $150.00K 10-Q · filed 2016-03-11 | $250.00K derived: sum of 3 quarters · filed 2016-03-11 | $250.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2015-09-30 | $50.00K 10-Q · filed 2015-11-13 | $150.00K derived: sum of 2 quarters · filed 2015-11-13 | $150.00K derived: sum of 3 quarters · filed 2015-11-13 | $300.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2015-06-30 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-25 | $100.00K derived: sum of 2 quarters · filed 2015-09-25 | $250.00K derived: sum of 3 quarters · filed 2016-03-11 | $340.00K 10-K · filed 2015-09-25 |
| 2015-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | $150.00K derived: sum of 2 quarters · filed 2016-03-11 | $240.00K 10-Q · filed 2015-05-11 | $240.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-12-31 | $150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-03-11 | $240.00K 10-Q · filed 2016-03-11 | $240.00K derived: sum of 3 quarters · filed 2016-03-11 | $415.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-09-30 | $90.00K 10-Q · filed 2015-11-13 | $90.00K derived: sum of 2 quarters · filed 2015-11-13 | $265.00K derived: sum of 3 quarters · filed 2015-11-13 | $265.00K derived: sum of 4 quarters · filed 2015-11-13 |
| 2014-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-25 | $175.00K derived: sum of 2 quarters · filed 2015-09-25 | $175.00K derived: sum of 3 quarters · filed 2015-09-25 | $175.00K 10-K · filed 2015-09-25 |
| 2014-03-31 | $175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | $175.00K derived: sum of 2 quarters · filed 2015-05-11 | $175.00K 10-Q · filed 2015-05-11 | |
| 2013-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-06 | $0.00 10-Q · filed 2015-02-06 | ||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |